Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma.

Autor:	Bourdin A; Department of Respiratory Diseases, Université de Montpellier, CHU Montpellier, PhyMedExp, INSERM, CNRS, Montpellier, France., Shaw D; Division of Respiratory Medicine, University of Nottingham, Nottingham, UK., Menzies-Gow A; Department of Respiratory Medicine, Royal Brompton Hospital, London, UK., FitzGerald JM; Centre for Heart and Lung Health, The Lung Centre Vancouver General Hospital, UBC Institute for Heart and Lung Health, Vancouver, Canada., Bleecker ER; Divisions of Pharmacogenomics and Genetics, Genomics and Precision Medicine, University of Arizona College of Medicine, Tucson, AZ, USA., Busse WW; Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA., Ferguson GT; Pulmonary Medicine, Internal Medicine, Critical Care Medicine, Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA., Brooks L; Research and Development, AstraZeneca, Gaithersburg, MD, USA., Barker P; Research and Development, AstraZeneca, Gaithersburg, MD, USA., Gil EG; Global Medical Affairs, AstraZeneca, Barcelona, Spain., Martin UJ; Research and Development, AstraZeneca, Gaithersburg, MD, USA.
Jazyk:	angličtina
Zdroj:	The Journal of asthma : official journal of the Association for the Care of Asthma [J Asthma] 2021 Apr; Vol. 58 (4), pp. 514-522. Date of Electronic Publication: 2019 Dec 26.
DOI:	10.1080/02770903.2019.1705333
Abstrakt:	Objective: Treatment with benralizumab significantly reduces exacerbations and improves lung function after 1 year and decreases oral corticosteroid (OCS) use after 28 weeks for patients with severe, uncontrolled eosinophilic asthma. We assessed whether these effects on OCS reduction are sustained for up to an additional year of treatment while maintaining an acceptable safety profile. Methods: Data on OCS maintenance dosage were collected for adult patients with baseline blood eosinophil counts ≥150 cells/μL treated with add-on benralizumab 30 mg (every 4 [Q4W] or 8 weeks [Q8W; first three doses Q4W]) from the 28-week ZONDA study and were integrated with results from the predefined 56-week adult completion phase of the BORA extension study. Efficacy and safety were summarized descriptively. Results: For patients receiving benralizumab Q8W, the median daily OCS dosage reduction of 75% from baseline to end of treatment achieved in ZONDA was sustained at the end of the BORA extension period (median 67% reduction from baseline). This was estimated to result in a median cumulative OCS dosage of 2.98 g over the 1.5-year period for patients receiving benralizumab Q8W compared with 5.74 g if these patients had remained on their baseline OCS dosages prior to benralizumab initiation. All adverse event rates were similar between the BORA extension and ZONDA periods, with no new or unexpected safety findings. Conclusion: This benralizumab 1.5-year integrated analysis demonstrates that OCS reductions and safety were maintained with further follow up and supports long-term use of benralizumab for patients with severe, uncontrolled eosinophilic asthma.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu